Data from: Impact of directly observed treatment and extended age-range of seasonal malaria chemoprevention with sulfadoxine–pyrimethamine plus amodiaquine in Burkina Faso: A three-arm, open-label, cluster-randomized, controlled trial

Seasonal Malaria Chemoprevention (SMC) currently targets children below 5 years (< 5 yr). It is unclear what the impact of extending SMC to a wider age range will be. We conducted a cluster-randomized trial in Saponé (Burkina Faso) with three study arms: 1) Programmatic SMC-control arm: SMC in children < 5 years; 2) SMC in children < 5 years, with directly observed treatment (DOTu5); 3) SMC in children < 10 years with DOT (DOTu10). The trial involved 61 (programmatic SMC) and 62 (each DOT arms) clusters of 3 compounds (i.e., 183-186 compounds per arm). The primary endpoint was P. falciparum parasite prevalence at the end of the transmission season; secondary endpoints included clinical malaria incidence, drug plasma levels, and gametocyte prevalence. This trial is complete and is registered with ClinicalTrials.gov, NCT05878366.